Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome

Gonzalo Laje, Rebecca Bernert, Rebecca Morse, Maryland Pao, Ann C M Smith

Research output: Contribution to journalArticle

Abstract

Smith-Magenis syndrome (SMS) is a complex genetic syndrome caused by an interstitial deletion of chromosome 17p11.2. Children and adults with SMS appear to have unique neurobehavioral problems that include: sleep disturbance, self-injurious and maladaptive behaviors, stereotypies, and sensory integration disorders. We gathered retrospective psychotropic use information from parents or other caregivers of 62 individuals with SMS who were asked about use of psychotropic medication from a list of commonly used psychiatric medications. For those drugs identified, respondents were asked to rate the experience with the particular medication using a likert-type scale. Drugs were grouped into seven main categories: (1) stimulants; (2) antidepressants; (3) antipsychotics; (4) sleep aides; (5) mood stabilizers; (6) alpha 2 agonists; and (7) benzodiazepines. Relative frequencies, means and standard deviations pertaining to age and medication effect were derived for each medication category. Six of the seven medication categories examined showed no meaningful deviations from the "no change" score. The benzodiazepine group showed a mild detrimental effect. There were no gender differences in efficacy. Use of psychotropic medication started early in life (mean age 5 years), particularly with sleep aides. Although no medication category was identified as efficacious in SMS, all the categories reported herein may be considered as an option for brief symptomatic relief. Published 2010 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)463-468
Number of pages6
JournalAmerican Journal of Medical Genetics, Part A
Volume154
Issue number4
DOIs
StatePublished - Nov 2010

Fingerprint

Smith-Magenis Syndrome
Pharmacology
Sleep
Benzodiazepines
Sensation Disorders
Self-Injurious Behavior
Chromosome Deletion
Therapeutics
Pharmaceutical Preparations
Antidepressive Agents
Caregivers
Antipsychotic Agents
Psychiatry
Parents
Problem Behavior

Keywords

  • Aggression
  • Autism
  • Genetics
  • Melatonin
  • Mental retardation
  • Pharmacogenetics
  • Pharmacogenomics
  • Pharmacology
  • Self-injurious behavior
  • Sleep
  • Smith-Magenis syndrome (SMS)
  • Treatment

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. / Laje, Gonzalo; Bernert, Rebecca; Morse, Rebecca; Pao, Maryland; Smith, Ann C M.

In: American Journal of Medical Genetics, Part A, Vol. 154, No. 4, 11.2010, p. 463-468.

Research output: Contribution to journalArticle

Laje, Gonzalo ; Bernert, Rebecca ; Morse, Rebecca ; Pao, Maryland ; Smith, Ann C M. / Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. In: American Journal of Medical Genetics, Part A. 2010 ; Vol. 154, No. 4. pp. 463-468.
@article{bc55124229d4436e985c768935b81e6d,
title = "Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome",
abstract = "Smith-Magenis syndrome (SMS) is a complex genetic syndrome caused by an interstitial deletion of chromosome 17p11.2. Children and adults with SMS appear to have unique neurobehavioral problems that include: sleep disturbance, self-injurious and maladaptive behaviors, stereotypies, and sensory integration disorders. We gathered retrospective psychotropic use information from parents or other caregivers of 62 individuals with SMS who were asked about use of psychotropic medication from a list of commonly used psychiatric medications. For those drugs identified, respondents were asked to rate the experience with the particular medication using a likert-type scale. Drugs were grouped into seven main categories: (1) stimulants; (2) antidepressants; (3) antipsychotics; (4) sleep aides; (5) mood stabilizers; (6) alpha 2 agonists; and (7) benzodiazepines. Relative frequencies, means and standard deviations pertaining to age and medication effect were derived for each medication category. Six of the seven medication categories examined showed no meaningful deviations from the {"}no change{"} score. The benzodiazepine group showed a mild detrimental effect. There were no gender differences in efficacy. Use of psychotropic medication started early in life (mean age 5 years), particularly with sleep aides. Although no medication category was identified as efficacious in SMS, all the categories reported herein may be considered as an option for brief symptomatic relief. Published 2010 Wiley-Liss, Inc.",
keywords = "Aggression, Autism, Genetics, Melatonin, Mental retardation, Pharmacogenetics, Pharmacogenomics, Pharmacology, Self-injurious behavior, Sleep, Smith-Magenis syndrome (SMS), Treatment",
author = "Gonzalo Laje and Rebecca Bernert and Rebecca Morse and Maryland Pao and Smith, {Ann C M}",
year = "2010",
month = "11",
doi = "10.1002/ajmg.c.30282",
language = "English (US)",
volume = "154",
pages = "463--468",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome

AU - Laje, Gonzalo

AU - Bernert, Rebecca

AU - Morse, Rebecca

AU - Pao, Maryland

AU - Smith, Ann C M

PY - 2010/11

Y1 - 2010/11

N2 - Smith-Magenis syndrome (SMS) is a complex genetic syndrome caused by an interstitial deletion of chromosome 17p11.2. Children and adults with SMS appear to have unique neurobehavioral problems that include: sleep disturbance, self-injurious and maladaptive behaviors, stereotypies, and sensory integration disorders. We gathered retrospective psychotropic use information from parents or other caregivers of 62 individuals with SMS who were asked about use of psychotropic medication from a list of commonly used psychiatric medications. For those drugs identified, respondents were asked to rate the experience with the particular medication using a likert-type scale. Drugs were grouped into seven main categories: (1) stimulants; (2) antidepressants; (3) antipsychotics; (4) sleep aides; (5) mood stabilizers; (6) alpha 2 agonists; and (7) benzodiazepines. Relative frequencies, means and standard deviations pertaining to age and medication effect were derived for each medication category. Six of the seven medication categories examined showed no meaningful deviations from the "no change" score. The benzodiazepine group showed a mild detrimental effect. There were no gender differences in efficacy. Use of psychotropic medication started early in life (mean age 5 years), particularly with sleep aides. Although no medication category was identified as efficacious in SMS, all the categories reported herein may be considered as an option for brief symptomatic relief. Published 2010 Wiley-Liss, Inc.

AB - Smith-Magenis syndrome (SMS) is a complex genetic syndrome caused by an interstitial deletion of chromosome 17p11.2. Children and adults with SMS appear to have unique neurobehavioral problems that include: sleep disturbance, self-injurious and maladaptive behaviors, stereotypies, and sensory integration disorders. We gathered retrospective psychotropic use information from parents or other caregivers of 62 individuals with SMS who were asked about use of psychotropic medication from a list of commonly used psychiatric medications. For those drugs identified, respondents were asked to rate the experience with the particular medication using a likert-type scale. Drugs were grouped into seven main categories: (1) stimulants; (2) antidepressants; (3) antipsychotics; (4) sleep aides; (5) mood stabilizers; (6) alpha 2 agonists; and (7) benzodiazepines. Relative frequencies, means and standard deviations pertaining to age and medication effect were derived for each medication category. Six of the seven medication categories examined showed no meaningful deviations from the "no change" score. The benzodiazepine group showed a mild detrimental effect. There were no gender differences in efficacy. Use of psychotropic medication started early in life (mean age 5 years), particularly with sleep aides. Although no medication category was identified as efficacious in SMS, all the categories reported herein may be considered as an option for brief symptomatic relief. Published 2010 Wiley-Liss, Inc.

KW - Aggression

KW - Autism

KW - Genetics

KW - Melatonin

KW - Mental retardation

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - Pharmacology

KW - Self-injurious behavior

KW - Sleep

KW - Smith-Magenis syndrome (SMS)

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=78049364470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049364470&partnerID=8YFLogxK

U2 - 10.1002/ajmg.c.30282

DO - 10.1002/ajmg.c.30282

M3 - Article

C2 - 20981776

AN - SCOPUS:78049364470

VL - 154

SP - 463

EP - 468

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 4

ER -